ArticleBioresources and bioprocessing2026
CYP1B1 is a potential target of kaempferol in renal fibrosis: a multi‑omics and single‑cell transcriptomics study.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRenal fibrosis (RF) is a progressive and irreversible pathological process for which effective treatments are limited. This study explores the molecular targets and mechanisms through which kaempferol (Kae) ameliorates RF, with particular emphasis on cytochrome P450 1B1 (CYP1B1).
methodsUsing a combination of transcriptomic profiling, weighted gene co‑expression network analysis (WGCNA), multi‑algorithm machine learning [least absolute shrinkage and selection operator (LASSO), support vector machine‑recursive feature elimination (SVM‑RFE), and Random Forest], and single‑cell transcriptomics, we identified the core targets of Kae intervention in RF. shapley additive explanations (SHAP) analysis evaluated gene contributions to the predictive model, while cell‑type identification by estimating relative subsets of RNA transcripts (CIBERSORT) estimated the immune microenvironment. The cell type-specific distribution of core targets was further characterized through single-cell RNA sequencing (scRNA-seq), and the scTenifoldKnk (a machine learning-based virtual gene knockout tool) algorithm simulated the effects of CYP1B1 loss-of-function on fibroblast activation and extracellular matrix (ECM) deposition. Finally, molecular docking was performed to predict the binding conformations of kaempferol with the proteins encoded by the six prioritized genes.
resultsSix core genes (VCAM1, NFKBIA, SFN, CCL5, CYP1B1, and AXL) were identified from 25 Kae-RF-related genes, with CYP1B1 as an upstream regulatory hub. Immune infiltration analysis revealed increased plasma cells and eosinophils, alongside decreased M0/M1 macrophages and activated NK cells. Single-cell analysis localized CYP1B1 to smooth muscle cells and fibroblasts, with significant upregulation during late-stage fibroblast-to-myofibroblast differentiation. Virtual knockdown of CYP1B1 upregulated 46 genes associated with fibrosis-related biological processes, including cell adhesion, G protein-coupled receptor (GPCR) signaling, ion transport, and cytoskeletal remodeling. The six-gene diagnostic model achieved area under the curves (AUCs) of 0.889 (training) and 0.759 (external validation). Molecular docking showed favorable Kae-CYP1B1 binding (- 6.5 kcal/mol).
conclusionCYP1B1 may serve as a potential functional target of Kae in RF, likely through modulation of fibroblast activation and ECM remodeling. These findings are hypothesis‑generating and provide a computational basis for future experimental validation of CYP1B1‑targeted strategies in RF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.